Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2008 17:25 ET | Source: Novogen, Limited

Novogen's NV-128 Is a Unique Inhibitor of mTOR Dephosphorylation Leading to Caspase Independent Death in Chemoresistant Cancer Cells

SAN DIEGO, CA--(Marketwire - April 15, 2008) - Pre-clinical studies reviewed during an oral presentation here today at the annual meeting of the American Association for Cancer Research demonstrate...
April 13, 2008 16:00 ET | Source: Marshall Edwards, Inc.

Marshall Edwards, Inc.'s Investigational Drug Triphendiol (NV-196) Demonstrates Potent Activity Against Biliary Cancers

SAN DIEGO, CA--(Marketwire - April 13, 2008) - Pre-clinical studies presented here today at the annual meeting of the American Association for Cancer Research demonstrate that Marshall Edwards,...
April 02, 2008 08:00 ET | Source: Novogen, Limited

Novogen Cardiovascular Drug Enters Phase I Clinical Trial

SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - April 2, 2008) - Novogen today announced the commencement of a Phase I human clinical trial of the novel cardiovascular drug, NV-27. This drug is...
March 26, 2008 08:00 ET | Source: Union Green

Union Green's Mission: to Become Earth's "Friendliest" Advertising Agency

NEW YORK, NY--(Marketwire - March 26, 2008) - New York-based brand and advertising agency, Union, announced today the launch of Union Green, a new agency that will define, create and execute...
March 25, 2008 08:02 ET | Source: Marshall Edwards, Inc.

Data to Be Presented at AACR Reveals That the Marshall Edwards' Compound Triphendiol May Aid in Treatment of Pancreatic Cancer

NEW CANAAN, CT--(Marketwire - March 25, 2008) - The abstract for a "late breaking" presentation at the Annual Meeting of the American Association for Cancer Research, April 12-16, San Diego, Calif.,...
March 25, 2008 08:01 ET | Source: NOVOGEN LIMITED

Yale Researchers to Present Data at AACR Conference Indicating That Novogen Compound NV-128 Uses mTOR Pathway to Induce Cell Death in Chemo-Resistant Ovarian Cancer Cells

SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - March 25, 2008) - An abstract for an oral presentation to be given at the Annual Meeting of the American Association for Cancer Research, April 12...
March 10, 2008 08:00 ET | Source: Marshall Edwards, Inc.

Phenoxodiol Trials Highlighted at Ovarian Cancer Action International Conference

SYDNEY, AUSTRALIA and LONDON and NEW CANAAN, CT--(Marketwire - March 10, 2008) - The role of the investigational drug phenoxodiol in restoration of chemosensitivity in ovarian cancer patients...
February 19, 2008 07:31 ET | Source: Marshall Edwards, Inc.

Additional Orphan Drug Status Granted for Melanoma for Marshall Edwards' Investigational Anti-Cancer Drug Triphendiol (NV-196)

NEW CANAAN, CT--(Marketwire - February 19, 2008) - Marshall Edwards, Inc., (NASDAQ: MSHL) announced today that triphendiol (previously known as NV-196) has been granted Orphan Drug status by the U.S....
February 04, 2008 14:32 ET | Source: WHITECOAT Strategies, LLC

WHITECOAT Strategies, LLC, Opens for Business, Challenges Clients to "Put More Life in Your Science"

WASHINGTON, DC--(Marketwire - February 4, 2008) - With over 100 years of collective staff experience, WHITECOAT Strategies, LLC, opens today to serve science and technology driven clients, including...
January 22, 2008 08:54 ET | Source: Marshall Edwards, Inc.

Orphan Drug Status Granted for Marshall Edwards' Investigational Anti-Cancer Drug Triphendiol (NV-196)

NEW CANAAN, CT--(Marketwire - January 22, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) announced today that its triphendiol (previously known as NV-196) has been granted orphan drug status by the...